Healthcare, Pharma & Life Sciences

CPSC Names Paul Brubaker Executive Director, Chief Operating Officer

Image
CPSC Names Paul Brubaker Executive Director, Chief Operating Officer

Washington, D.C. – September 17, 2026 -- The U.S. Consumer Product Safety Commission has appointed Paul Brubaker as its new Executive Director, installing him as the agency's chief operating officer over programmatic, operational, and administrative functions.

Brubaker takes charge of CPSC's regulatory portfolio and hazard-response operations

Brubaker will manage CPSC's regulatory portfolio and help direct efforts to identify and address consumer product hazards. He brings nearly four decades of public and private sector leadership in technology, cybersecurity, data analytics, organizational strategy, and federal management.

CTI's Crystal Risotti Named Pinnacle Professional by The Inner Circle

Image
CTI's Crystal Risotti Named Pinnacle Professional by The Inner Circle

Indianapolis – September 17, 2026 -- Crystal Risotti, Senior Manager of Validation in Quality Assurance at CTI, has been named a Pinnacle Professional of the Year by The Inner Circle for her three-decade career in information technology quality assurance and regulatory compliance across pharmaceuticals, medical devices and clinical laboratories.

Risotti built her career from clinical trial lab work in 1990 to enterprise-wide compliance leadership

Risotti entered the pharmaceutical industry in 1990 as a clinical trials laboratory worker before moving through customer service, project management, training and Tier 4 help desk roles. She later specialized in software development life cycle consultation, 21 CFR Part 11 compliance, and electronic quality management system implementation, working remotely from Indianapolis, Indiana while based at CTI's Covington, Kentucky office.

Seismic Dosing First Patient in Phase 3 Cardiogenic Shock Trial

Durham – September 17, 2026 -- Seismic Pharmaceuticals has enrolled the first patient in its global Phase 3 trial testing istaroxime for heart-failure-related cardiogenic shock, a condition with no FDA-approved pharmacologic therapy. The study, RESCUE HF-CS, targets approximately 600 patients recruited at clinical sites across the United States, Europe, China and South America.

No approved drug currently exists for cardiogenic shock, a high-mortality condition

Cardiogenic shock occurs when the heart cannot pump enough blood to meet the body's needs, cutting off oxygen delivery to vital organs. Despite advances in critical care, the condition continues to carry high complication and mortality rates, and no medication has been specifically approved to treat it.

Hikma's Epinephrine Nasal Spray Advances Through FDA, EU, UK Review

Image
Hikma's Epinephrine Nasal Spray Advances Through FDA, EU, UK Review

London – September 17, 2026 -- Hikma Pharmaceuticals PLC said regulators in the United States, Europe, and the UK have accepted for review its investigational epinephrine nasal spray, a needle-free treatment for anaphylaxis, with an additional filing lodged in Canada.

FDA accepts 505(b)(2) application for non-injectable anaphylaxis treatment

The US Food and Drug Administration has taken up a New Drug Application submitted under the 505(b)(2) pathway, which includes the required non-clinical and clinical data package supporting approval of the nasal spray for emergency anaphylaxis treatment.

Franklin Pierce University Partners with Uwill for Grad Student Mental Health

Image
Franklin Pierce University Partners with Uwill for Grad Student Mental Health

Natick, Mass. – September 17, 2026 -- Franklin Pierce University has partnered with Uwill to expand mental health and wellness support for its graduate students, granting them unlimited access to licensed counselors through Uwill's teletherapy matching platform.

Nearly 40% of graduate students report anxiety or depression symptoms, six times the general population rate

The partnership responds to survey data showing 90% of adults believe the U.S. faces a mental health crisis, with graduate students facing disproportionately high rates of psychological distress tied to academic, career and family pressures.

SHIFT Names Trauma Expert Dr. Luedtke to New Advisory Council

Image
SHIFT Names Trauma Expert Dr. Luedtke to New Advisory Council

Austin – September 16, 2026 -- SHIFT, a health and performance platform built for industrial and frontline workforces, has launched a Clinical & Performance Advisory Council and named clinical psychologist Dr. Brandi Luedtke, PsyD, HSPP, as its Founding Advisor.

Construction suicide rates far exceed workplace fatality figures

Approximately 5,200 construction workers aged 16 to 64 died by suicide in 2022, more than five times the number who died from fatal workplace injuries, according to data analyzed by CPWR–The Center for Construction Research and Training. CDC figures for 2021 show men in construction had a suicide rate of 56.0 per 100,000, compared with 32.0 per 100,000 among men in the overall working population.

Helix Launches WES+ Test Combining Exome, Mitochondrial, Karyotype Analysis

Image
Helix Launches WES+ Test Combining Exome, Mitochondrial, Karyotype Analysis

San Mateo, Calif. – September 16, 2026 -- Helix has launched Whole Exome+ Sequencing (WES+), a diagnostic test that combines exome sequencing, mitochondrial genome analysis, and genome-wide digital karyotype into a single order for patients with unexplained developmental delay, neurological conditions, and rare genetic disease.

WES+ integrates four diagnostic capabilities in one order

The test covers 99% of clinically relevant exome regions, includes mitochondrial testing that other labs typically bill as a separate add-on, and performs high-resolution chromosomal copy number analysis via a digital karyotype. Helix says the digital karyotype feature may eliminate the need for a standalone chromosomal microarray (CMA) in many clinical scenarios, though the company notes CMA or additional cytogenetic testing may still be clinically indicated in some cases.

EMD Serono Acquires PostEra's AI-Designed Fertility Drug Programs

Image
EMD Serono Acquires PostEra's AI-Designed Fertility Drug Programs

Boston – September 16, 2026 -- EMD Serono, Inc., the U.S. and Canada healthcare business of Merck KGaA, Darmstadt, Germany, has acquired two preclinical fertility drug programs from Boston-based biotech PostEra, the companies announced.

EMD Serono takes over two AI-designed oral fertility candidates

The deal covers PostEra's Follicle-Stimulating Hormone Receptor (FSHR) agonist program for ovarian stimulation in IVF and its Luteinizing Hormone/Choriogonadotropin Receptor (LHCGR) agonist program for male infertility and ovulation triggering. Both programs originated from PostEra's proprietary Proton AI platform, developed over the past two years to target small-molecule alternatives in Women's Health and Fertility, markets the company describes as almost entirely dependent on injectable medications.

Carolina Complete Health Draws 205 to Six Baby Shower Events

Image
Carolina Complete Health Draws 205 to Six Baby Shower Events

Charlotte, N.C. – September 16, 2026 -- Approximately 205 participants attended Carolina Complete Health Community Baby Showers held Sept. 2 across six North Carolina communities, connecting expectant and new parents with maternal and infant health resources.

Six cities hosted events with 17 community partners

Families gathered at Carolina Complete Health Community Connections Centers in Asheville, Charlotte, Greensboro, Greenville, Lumberton and Raleigh. The events included participation from 17 community partners, expanding access to local services for prenatal care, breastfeeding, newborn care, nutrition and food assistance.

WBANA Launches Free Phytonutrient Education Toolkit for Back-to-School Season

Image
WBANA Launches Free Phytonutrient Education Toolkit for Back-to-School Season

Old Town, Maine – September 16, 2026 -- The Wild Blueberry Association of North America (WBANA) has released a free consumer-education toolkit designed to simplify scientific terminology around plant compounds for reporters, educators, parents and caregivers ahead of the back-to-school season.

WBANA responds to rising consumer confusion over bioactive compound terminology

Colleen Craig, who leads WBANA's Health Research Committee, said the trade group observed a surge in consumer publications using bioactive compound terms when discussing wild blueberries, generating increased customer questions about phytonutrients such as anthocyanins and antioxidants. The toolkit, titled 'The ABCs of Phytonutrients: A Back-to-School Guide to Wild Blueberry Plant Power,' is positioned as a first-step communications resource for the industry.